Corporate
Corcept Crashes 50% After FDA Rejects Relacorilant for Cushing's Syndrome
Jan 1
You're signed outSign in or to get full access.
CT
CORCEPT THERAPEUTICS (CORT)·Earnings Reports
Q3 2025
View earnings summary and analysis
Q2 2025
View earnings summary and analysis
Q1 2025
View earnings summary and analysis
Q4 2024
View earnings summary and analysis
Research analysts covering CORCEPT THERAPEUTICS.